By Fineline Cube Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting‑edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness artificial intelligence to conduct translational medicine research focused on Hanx Bio’s core bispecific antibody therapeutic candidate, HX009.
Collaboration Overview
| Item | Detail |
|---|---|
| Parties | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) × TwinEdge Bioscience (Switzerland) |
| Deal Type | AI‑driven translational medicine research collaboration |
| Focus Asset | HX009 — core bispecific antibody therapeutic candidate |
| Technology | TwinEdge’s proprietary AI models and computational biology tools |
| Disease Focus | Diffuse large B‑cell lymphoma (DLBCL) |
| Announcement Date | 2 Jul 2026 |
Scope of Work – AI‑Driven “Digital Twin” Development
Under the agreement, TwinEdge Bioscience will use its proprietary AI models and tools to develop personalized “Digital Twins” (or Avatars) based on a series of diffuse large B‑cell lymphoma (DLBCL) patient‑derived xenograft (PDX) mouse models. The partnership aims to:
- Further elucidate HX009’s mechanism of action
- Simulate HX009’s potential clinical performance in lymphoma patients
- Explore the applicability and relevance of this mechanism in DLBCL
Drug Profile – HX009
| Attribute | Detail |
|---|---|
| Molecule Type | Innovative bifunctional anti‑PD‑1/SIRPα fusion protein |
| Positioning | Novel, next‑generation PD‑1 therapy designed to enhance PD‑1 function |
| Mechanism | Synergistically binds CD8+ effector T cells within the tumor microenvironment (TIL‑Teff) and dual‑targets both PD‑1 and CD47 receptors on these cells |
| Effect | Boosts anti‑tumor immunity |
| Clinical Status | Recently completed clinical proof‑of‑concept (POC) study for EBV‑positive non‑Hodgkin lymphoma (including EBV‑positive DLBCL) |
| Next Milestone | Plans to initiate pivotal clinical trials for this indication |
Strategic Rationale & Market Impact
- AI Meets Bispecifics: The collaboration pairs Hanx Bio’s bispecific antibody asset with TwinEdge’s computational biology platform, using AI‑powered Digital Twins to de‑risk clinical development and sharpen mechanistic understanding ahead of pivotal trials.
- Next‑Generation PD‑1 Positioning: HX009’s dual‑targeting anti‑PD‑1/SIRPα design aims to improve on the crowded PD‑1 inhibitor landscape by enhancing effector T‑cell function within the tumor microenvironment — a key differentiator in immuno‑oncology.
- DLBCL Opportunity: DLBCL is the most common subtype of non‑Hodgkin lymphoma, with substantial unmet need in relapsed and hard‑to‑treat populations, including EBV‑positive disease.
- POC‑to‑Pivotal Momentum: Having completed a clinical POC study in EBV‑positive NHL, Hanx Bio’s plan to move into pivotal trials gives the collaboration a near‑term clinical catalyst that AI modeling can help optimize.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration’s research outcomes, HX009’s clinical performance, and pivotal trial plans. Actual results may differ due to risks including translational research findings, regulatory pathways, and competitive dynamics.-Fineline Info & Tech